BioLife Solutions, Inc. (BLFS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.77M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 21.64M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.77M | (m) | $21.64M | $1.75M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $8.78M | (m) | $23.65M | $-16.08M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $7.57M | (m) | $22.99M | $-16.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $9.55M | (m) | $26.61M | $-20.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $8.73M | (m) | $26.03M | $-20.39M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $8.04M | (m) | $28.89M | $-5.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $7.91M | (m) | $30.92M | $-7.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $14.85M | (m) | $28.56M | $-44.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $16.54M | (m) | $32.35M | $-58.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $18.18M | (m) | $30.49M | $-67.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $18.80M | (m) | $31.67M | $-70.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $18.56M | (m) | $31.00M | $-106.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $16.58M | (m) | $28.18M | $-89.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $15.17M | (m) | $27.30M | $-151.18M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $14.80M | (m) | $25.33M | $-145.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $14.21M | (m) | $22.74M | $-112.55M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $14.00M | (m) | $21.30M | $-112.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $13.62M | (m) | $17.85M | $-40.59M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $11.82M | (m) | $13.96M | $-33.94M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $10.11M | (m) | $11.05M | $-21.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $8.61M | (m) | $7.75M | $-11.52M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $7.04M | (m) | $6.37M | $-6.93M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.72M | (m) | $5.98M | $-5.58M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $5.95M | (m) | $4.68M | $-1.59M | $4.00K | (m) | (m) | -398.25× | Reported |
| 2020-06-30 | $5.26M | (m) | $3.95M | $-1.12M | $2.00K | (m) | (m) | -559.50× | Reported |
| 2020-03-31 | $4.47M | (m) | (m) | $-416.00K | $3.00K | (m) | (m) | -138.67× | Reported |
| 2019-12-31 | $3.17M | (m) | $3.04M | $-220.00K | $5.00K | (m) | (m) | -44.00× | Reported |
| 2019-09-30 | $2.73M | (m) | $2.29M | $1.86M | $6.00K | (m) | (m) | 309.33× | Reported |
| 2019-06-30 | $1.74M | (m) | $2.02M | $3.65M | $8.00K | (m) | (m) | 456.00× | Reported |
| 2019-03-31 | $1.32M | (m) | $1.75M | $4.01M | $7.00K | (m) | (m) | 573.29× | Reported |
| 2019-03-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.30M | (m) | $1.52M | $3.66M | $5.00K | (m) | (m) | 732.40× | Reported |
| 2018-09-30 | $1.28M | (m) | $1.44M | $2.40M | $4.62K | (m) | (m) | 519.52× | Reported |
| 2018-06-30 | $1.26M | (m) | $1.37M | $1.17M | $4.39K | (m) | (m) | 267.64× | Reported |
| 2018-03-31 | $1.25M | (m) | $1.31M | $-452.09K | $107.64K | (m) | (m) | -4.20× | Reported |
| 2018-03-30 | (m) | (m) | $1.31M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $1.19M | (m) | $1.27M | $-1.06M | $190.07K | (m) | (m) | -5.56× | Reported |
| 2017-09-30 | $1.33M | (m) | $1.15M | $-1.46M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $1.53M | (m) | $1.02M | $-2.57M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.81M | (m) | $960.36K | $-3.82M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $2.03M | (m) | $776.99K | $-4.85M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $2.03M | (m) | $758.67K | $-5.63M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $1.86M | (m) | $755.85K | $-5.79M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $1.56M | (m) | $624.48K | $-5.35M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $1.38M | (m) | $511.46K | $-5.02M | $0.00 | (m) | (m) | (m) | Reported |
| 2015-09-30 | $1.31M | (m) | $382.81K | $-4.62M | $0.00 | (m) | (m) | (m) | Reported |
| 2015-06-30 | $1.13M | (m) | $278.87K | $-4.20M | $0.00 | (m) | (m) | (m) | Reported |
| 2015-03-31 | $1.03M | (m) | $211.57K | $-3.93M | $0.00 | (m) | (m) | (m) | Reported |
| 2014-12-31 | $871.10K | $6.19M | $229.68K | $-3.14M | $177.31K | 14.07% | 3.71% | -17.68× | Reported |
| 2014-09-30 | $639.80K | $6.81M | $255.92K | $-2.42M | $362.86K | 9.40% | 3.76% | -6.66× | Reported |
| 2014-06-30 | $647.00K | $7.74M | $269.83K | $-1.65M | $548.42K | 8.36% | 3.49% | -3.01× | Reported |
| 2014-03-31 | $549.13K | $8.85M | $232.44K | $-846.73K | $733.97K | 6.20% | 2.63% | -1.15× | Reported |
| 2013-12-31 | $487.82K | $8.95M | $248.20K | $-285.36K | $742.22K | 5.45% | 2.77% | -0.38× | Reported |
| 2013-09-30 | $471.20K | $8.71M | $237.13K | $-308.24K | $742.22K | 5.41% | 2.72% | -0.42× | Reported |
| 2013-06-30 | $421.37K | $8.22M | $206.03K | $-346.86K | $742.22K | 5.13% | 2.51% | -0.47× | Reported |
| 2013-03-31 | $453.08K | $6.99M | $236.79K | $-570.64K | $740.21K | 6.48% | 3.39% | -0.77× | Reported |
| 2012-12-31 | $463.64K | $5.66M | $216.09K | $-942.24K | $733.43K | 8.19% | 3.82% | -1.28× | Reported |
| 2012-09-30 | $479.20K | $4.42M | $206.93K | $-845.19K | $721.40K | 10.83% | 4.68% | -1.17× | Reported |
| 2012-06-30 | $467.42K | $3.46M | $201.58K | $-981.29K | $707.52K | 13.52% | 5.83% | -1.39× | Reported |
| 2012-03-31 | $474.18K | $2.98M | $203.90K | $-934.67K | $689.22K | 15.89% | 6.83% | -1.36× | Reported |
| 2011-12-31 | $516.45K | $2.76M | $235.84K | $-1.21M | $670.99K | 18.72% | 8.55% | -1.80× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $318.90K | $2.08M | $164.48K | $-1.39M | $588.00K | 15.32% | 7.90% | -2.37× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |